AAPL 165.84 0.5091% MSFT 400.96 0.461% GOOG 157.95 1.4321% GOOGL 156.28 1.4212% AMZN 177.23 1.4889% NVDA 795.18 4.3543% META 481.73 0.1372% TSLA 142.05 -3.4002% TSM 129.75 1.6053% LLY 731.33 0.6912% V 272.33 0.9452% AVGO 1224.46 1.6394% JPM 189.41 1.9429% UNH 491.23 -1.9755% NVO 125.26 2.0781% WMT 60.14 1.0247% LVMUY 168.89 0.4222% XOM 120.57 0.5756% LVMHF 851.89 0.4528% MA 456.75 0.2986%
Last update at 2024-04-22T20:02:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -112.32500M | -70.73800M | -60.94700M | -50.87800M | -151.94900M |
| Minority interest | - | - | - | - | - |
| Net income | -122.78300M | -70.51100M | -59.78000M | -50.37200M | -151.18400M |
| Selling general administrative | 27.20M | 20.49M | 14.46M | 15.43M | 19.27M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 2.36M | 4.65M | 7.42M | 3.57M | 9.54M |
| Reconciled depreciation | 2.90M | 3.07M | 3.93M | 4.86M | 3.80M |
| Ebit | -115.23400M | -71.24300M | -63.35400M | -55.03100M | -0.85900M |
| Ebitda | -101.86700M | -67.55800M | -38.19700M | -58.17200M | -0.63500M |
| Depreciation and amortization | 13.37M | 3.69M | 25.16M | -3.14100M | 0.22M |
| Non operating income net other | - | 0.51M | 2.41M | 4.15M | 4.49M |
| Operating income | -115.23400M | -71.24300M | -63.35400M | -55.03100M | -156.43600M |
| Other operating expenses | 109.45M | 73.80M | 56.99M | 58.10M | 85.94M |
| Interest expense | -2.90900M | 0.11M | 18.82M | 0.00000M | 151.09M |
| Tax provision | 0.00000M | -0.22700M | -1.16700M | 0.00000M | -0.76500M |
| Interest income | - | - | - | 4.15M | 4.49M |
| Net interest income | - | - | - | - | - |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | 3.50M | 18.00M | 1.80M | 109.65M |
| Other items | - | - | - | - | - |
| Income tax expense | 10.46M | -0.22700M | -1.16700M | -0.50600M | -0.76500M |
| Total revenue | 2.36M | 4.65M | 7.42M | 3.57M | 9.54M |
| Total operating expenses | 109.45M | 73.80M | 56.99M | 58.10M | 85.94M |
| Cost of revenue | - | - | - | 42.67M | 65.45M |
| Total other income expense net | 2.91M | 0.51M | 2.41M | 4.15M | -75.54500M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -112.32500M | -70.51100M | -59.78000M | -50.87800M | -151.18400M |
| Net income applicable to common shares | -112.32500M | -70.51100M | -59.78000M | -50.87800M | -151.18400M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 352.74M | 444.65M | 235.84M | 122.93M | 155.81M |
| Intangible assets | 31.30M | 30.26M | 34.18M | 52.20M | 50.62M |
| Earning assets | - | - | - | - | - |
| Other current assets | 12.74M | 2.59M | 3.42M | 2.31M | 5.06M |
| Total liab | 26.53M | 25.18M | 26.48M | 28.91M | 31.75M |
| Total stockholder equity | 326.20M | 419.48M | 209.36M | 94.03M | 124.06M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 13.82M | 1.55M | 3.37M | 2.03M | 4.53M |
| Common stock | 0.05M | 0.05M | 0.04M | 0.02M | 0.01M |
| Capital stock | 0.05M | 0.05M | 0.04M | 0.02M | 0.01M |
| Retained earnings | -1255.93200M | -1143.60700M | -1073.09600M | -1013.31600M | -962.43800M |
| Other liab | 5.33M | 7.35M | 10.12M | 15.55M | 19.15M |
| Good will | - | - | - | - | 0.00000M |
| Other assets | 0.10M | 0.10M | 0.04M | 0.04M | 0.13M |
| Cash | 29.43M | 39.14M | 43.84M | 11.23M | 24.31M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 18.61M | 16.53M | 14.21M | 11.64M | 12.60M |
| Current deferred revenue | - | 12.00M | 8.46M | 6.50M | 2.48M |
| Net debt | -25.39600M | -36.10100M | -40.35500M | -7.57500M | -19.78400M |
| Short term debt | 1.45M | 1.75M | 1.33M | 1.94M | 4.53M |
| Short long term debt | - | - | - | - | 4.53M |
| Short long term debt total | 4.03M | 3.04M | 3.48M | 3.66M | 4.53M |
| Other stockholder equity | 1580.83M | 1561.14M | 1279.82M | 1104.71M | 1083.90M |
| Property plant equipment | 7.75M | 6.52M | 7.26M | 4.03M | 6.11M |
| Total current assets | 317.69M | 410.84M | 197.84M | 66.70M | 99.08M |
| Long term investments | - | - | - | - | 1.80M |
| Net tangible assets | 299.01M | 392.29M | 178.67M | 45.34M | 75.37M |
| Short term investments | 275.52M | 369.11M | 150.59M | 53.15M | 69.71M |
| Net receivables | 0.35M | 0.17M | 1.80M | 1.01M | 3.16M |
| Long term debt | - | - | - | - | - |
| Inventory | -0.34700M | -0.17200M | -1.80200M | -1.01500M | -3.16200M |
| Accounts payable | 3.34M | 1.23M | 1.05M | 1.17M | 1.07M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 1.26M | 1.89M | 2.59M | 2.62M | 2.58M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.05M | 0.04M | 0.02M | 0.01M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -1143.60700M | -1073.09600M | -1013.31600M | -962.43800M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.10M | 0.10M | 0.04M | 0.04M | 1.93M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 35.04M | 33.81M | 37.99M | 56.23M | 56.73M |
| Capital lease obligations | 4.03M | 3.04M | 3.48M | 3.66M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 89.94M | -214.93400M | -98.21800M | 17.79M | 30.29M |
| Change to liabilities | 3.12M | 3.65M | 1.64M | -6.92000M | -16.37800M |
| Total cashflows from investing activities | 89.94M | -216.15600M | -98.21800M | 17.08M | 29.82M |
| Net borrowings | - | - | - | - | - |
| Total cash from financing activities | 4.08M | 272.37M | 171.23M | 16.26M | 29.44M |
| Change to operating activities | -6.84600M | -6.28100M | -1.15000M | -6.27600M | -1.48500M |
| Net income | -112.32500M | -70.51100M | -59.78000M | -50.87800M | -151.18400M |
| Change in cash | -9.71400M | -4.69300M | 32.60M | -13.07800M | -15.97800M |
| Begin period cash flow | 39.14M | 43.84M | 11.23M | 24.31M | 40.29M |
| End period cash flow | 29.43M | 39.14M | 43.84M | 11.23M | 24.31M |
| Total cash from operating activities | -103.73200M | -60.90900M | -40.40400M | -46.41500M | -75.23500M |
| Issuance of capital stock | 0.00000M | 269.89M | 170.79M | 16.25M | 29.02M |
| Depreciation | 2.90M | 3.07M | 3.93M | 4.86M | 3.80M |
| Other cashflows from investing activities | - | 0.03M | 0.06M | 0.02M | 0.34M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | 13.89M | 1.78M |
| Change to account receivables | -0.17500M | 1.57M | -0.78700M | -0.77700M | -0.77700M |
| Sale purchase of stock | - | 272.37M | 171.23M | 16.26M | 29.44M |
| Other cashflows from financing activities | 89.94M | 2.48M | 3.40M | 0.00900M | 0.42M |
| Change to netincome | 9.60M | 7.59M | 15.75M | 5.07M | 88.57M |
| Capital expenditures | 1.83M | 1.25M | 1.55M | 0.73M | 0.81M |
| Change receivables | - | 1.57M | -0.78700M | 2.27M | -0.77700M |
| Cash flows other operating | - | -72.38700M | -60.11400M | -50.55500M | -149.40100M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | -4.69300M | 32.60M | -13.07800M | -15.97800M |
| Change in working capital | -3.89800M | -1.05400M | -0.29900M | -4.32300M | -15.37200M |
| Stock based compensation | 15.61M | 8.95M | 3.92M | 4.55M | 8.08M |
| Other non cash items | -5.78900M | -1.13800M | 13.00M | -1.29400M | 80.20M |
| Free cash flow | -105.56000M | -62.15800M | -41.95600M | -47.14600M | -76.04800M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CLDX Celldex Therapeutics Inc |
0.87 2.29% | 38.85 | - | - | 473.35 | 8.38 | 420.08 | -13.9042 |
| NVO Novo Nordisk A/S |
2.55 2.08% | 125.26 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
3.76 3.07% | 126.26 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
5.64 1.43% | 399.92 | 30.40 | 24.75 | 10.68 | 6.25 | 9.52 | 20.36 |
| CSLLY CSL Ltd |
2.35 2.71% | 89.17 | 42.45 | 26.95 | 7.05 | 5.80 | 7.85 | 26.51 |
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. It has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Perryville III Building, Hampton, NJ, United States, 08827
| Name | Title | Year Born |
|---|---|---|
| Mr. Anthony S. Marucci M.B.A. | Founder, Pres, CEO & Director | 1962 |
| Dr. Tibor Keler | Founder, Chief Scientific Officer & Exec. VP | 1959 |
| Mr. Sam Martin | Sr. VP, CFO, Sec. & Treasurer | 1971 |
| Mr. Freddy A. Jimenez Esq. | Sr. VP & Gen. Counsel | 1969 |
| Dr. Diane C. Young M.D. | Sr. VP & Chief Medical Officer | 1957 |
| Prof. Joseph P. Schlessinger Ph.D. | Co-Founder & Member of Scientific Advisory Board | 1945 |
| Ms. Sarah Cavanaugh | Sr. VP of Corp. Affairs & Admin. | 1975 |
| Patrick Till | Sr. Director of Investor Relations & Corp. Communications | NA |
| Dr. Ronald A. Pepin | Chief Bus. Officer & Sr. VP | 1956 |
| Ms. Elizabeth Crowley | Chief Product Devel. Officer & Sr. VP | 1972 |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...